Swiss biopharma Obseva SA (NASDAQ: OBSV), which is developing orally administered, clinical-stage compounds to treat women's reproductive health conditions, announced a positive late-stage clinical readout Monday for its investigational compound to treat heavy menstrual bleeding due to uterine fibroids.
ObsEva saw its shares a decline steeply in early November due to a failed trial of nolasiban, another pipeline asset.
ObsEva's Study Results
The Phase 3 study dubbed PRIMROSE 2 met the primary and secondary efficacy endpoints, ObsEva said.
The study evaluated once-daily oral linzagolix in 100mg and 200mg doses, with and without hormonal add-back therapy, or ABT,
The primary efficacy endpoint was the reduction in heavy menstrual bleeding.
The responder rate was 93.9% for women receiving 200mg linzagolix with ABT and 56.7% for women receiving 100mg without ABT versus 29.4% for the placebo group. The company termed the response for the 200mg dose as "best-in-class."
Both doses achieved significant rates of amenorrhea, reduction in pain and improvement in quality of life, according to ObsEva.
Linzagolix also led to significant improvement in hemoglobin levels, a reduction in the number of days of bleeding and a reduction in uterine volume, the company said.
ObsEva noted a significant reduction in fibroid volume for the 200mg dose with ABT.
The safety profile was in-line with expectations, confirming that linzagolix was well-tolerated.
Why Linzagolix Data Is Important
Linzagolix is a GnRH antagonist that is being developed in late-stage studies for endometriosis and uterine fibroids.
ObsEva licensed the compound from the Japanese biotech Kissei in late 2015.
A dire need exists for non-surgical alternatives for uterine fibroids to reduce the effects of heavy menstrual bleeding.
"The prospects for a medical treatment with multiple dosing options would address a need for this diverse population of women. I am particularly impressed with the 94% responder rate and 80% amenorrhea rate that linzagolix has shown," Dr. Hugh Taylor, chair of obstetrics and gynecology at the Yale University, said in a statement.
The 50% response shown by patients taking the 100mg dose without ABT provides a meaningful option for women who cannot or do not want to take exogenous hormones.
ObsEva said it expects results form the Phase 3 PRIMROZSE 1 study conducted in the U.S. in the second quarter of 2020.
Provided the study also ends with positive results, the company plans to submit a Marketing Authorization Application in Europe by the end of 2020 and a New Drug Application in the U.S. by the first quarter of 2021.
ObsEva shares were down 13.79% at $3.94 at the time of publication Monday.
See more from Benzinga
- The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
- The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
- The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.